NCT05363358View on ClinicalTrials.gov

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CompletedOBSERVATIONAL
Enrollment

6,086

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Trial Locations (1)

12194

RTI Health Solutions, Durham

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
collaborator

Baxalta Innovations GmbH, now part of Shire

INDUSTRY

collaborator

RTI Health Solutions

OTHER

lead

Takeda

INDUSTRY

NCT05363358 - A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Biotech Hunter | Biotech Hunter